Research Paper Advance Articles
Comprehensive genomic characterization of programmed cell death-related genes to predict drug resistance and prognosis for patients with multiple myeloma
Figure 6. Risk models and pathway characteristics and drug sensitivity differ between patients in different MM risk groups. (A) HALLMARK pathway differences between high and low-risk subgroups. (B) Bubble plots of Risk score in the MMRF-COMPASS training set cohort and expression of key genes in the model versus drug IC50 values, size and color indicate the strength of the association. (C) Comparison of IC50 scores versus drugs between high and low-risk groups. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.